Form 4: CEO Rick Winningham's Tax-Related Share Disposition

Theravance Biopharma CEO Rick Winningham disposed of 15,394 ordinary shares to cover tax obligations from restricted stock unit vesting.

Summary

• Rick E. Winningham, Chief Executive Officer and Director of Theravance Biopharma, Inc., disposed of 15,394 ordinary shares.
• The transaction occurred on August 20, 2025, at a price of $13.39 per share.
• These shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• This was not an open market transaction.
• Following this transaction, Mr. Winningham beneficially owns 1,717,786 ordinary shares directly, 13,500 indirectly as custodian, and 92,567 indirectly by trust.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a routine tax-related disposition following RSU vesting, which is an expected part of executive compensation and does not indicate a change in company fundamentals.

Positives

• The transaction indicates the vesting of previously granted restricted stock units, which represents earned compensation for the executive.

Negatives

• A disposition of shares, even for tax purposes, reduces the executive's direct ownership stake, though this is a standard practice for RSU vesting.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies when restricted stock units vest. It does not reflect broader industry trends or specific competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal direct impact. The slight reduction in the CEO's direct ownership is a routine consequence of RSU vesting and tax withholding, not indicative of a change in confidence or company performance.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related share disposition by the CEO following the vesting of restricted stock units. Such transactions are standard practice and do not indicate any change in the company's fundamental performance or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Theravance Biopharma, TBPH, Rick Winningham, Form 4, Insider Transaction, Share Disposition, Restricted Stock Units, Tax Withholding, CEO, Director